We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Diabetes Drug Toujeo Positive in PK/PD Study
Read MoreHide Full Article
Sanofi (SNY - Free Report) presented full results from a pharmacokinetic/pharmacodynamic (PK/PD) study on Toujeo in comparison with insulin degludec for the treatment of type 1 diabetes at the 16th Annual Diabetes Technology Meeting, Bethesda, MD.
The randomized double-blind study on Toujeo (insulin glargine 300 Units/mL) demonstrated an overall flat PK/PD profile and a more evenly distributed exposure over 24 hours in the Toujeo arm, compared to insulin degludec, at both the dose levels (0.4 and 0.6 U/kg/day).
Moreover, Toujeo was found to have a more favorable safety profile than Degludec.
Toujeo is already marketed in the U.S. and EU.
Toujeo continues to perform well in key markets, peaking global sales of €167 million in the third quarter of 2016 on the back of a consistently strong performance in the U.S., where Toujeo now occupies 6.6% of the total basal insulin market.
Sanofi currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) , Cambrex Corp. and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has increased 19.4% year to date.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and have increased from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 10.9% year to date.
Vanda’s loss estimates have narrowed from 68 cents per share to 56 cents per share for 2016 while its earnings estimates have increased from 16 cents per share to 17 cents per share for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price surged 77.8% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sanofi (SNY) Diabetes Drug Toujeo Positive in PK/PD Study
Sanofi (SNY - Free Report) presented full results from a pharmacokinetic/pharmacodynamic (PK/PD) study on Toujeo in comparison with insulin degludec for the treatment of type 1 diabetes at the 16th Annual Diabetes Technology Meeting, Bethesda, MD.
The randomized double-blind study on Toujeo (insulin glargine 300 Units/mL) demonstrated an overall flat PK/PD profile and a more evenly distributed exposure over 24 hours in the Toujeo arm, compared to insulin degludec, at both the dose levels (0.4 and 0.6 U/kg/day).
Moreover, Toujeo was found to have a more favorable safety profile than Degludec.
Toujeo is already marketed in the U.S. and EU.
Toujeo continues to perform well in key markets, peaking global sales of €167 million in the third quarter of 2016 on the back of a consistently strong performance in the U.S., where Toujeo now occupies 6.6% of the total basal insulin market.
SANOFI-AVENTIS Price
SANOFI-AVENTIS Price | SANOFI-AVENTIS Quote
Zacks Rank & Key Picks
Sanofi currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Anika Therapeutics Inc. (ANIK - Free Report) , Cambrex Corp. and Vanda Pharmaceuticals, Inc. (VNDA - Free Report) . Each of these stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates have increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted a positive earnings surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has increased 19.4% year to date.
Cambrex’s earnings estimates have increased from $2.46 to $2.55 for 2016 and have increased from $2.91 to $3.06 for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 19.78%. Its share price has increased 10.9% year to date.
Vanda’s loss estimates have narrowed from 68 cents per share to 56 cents per share for 2016 while its earnings estimates have increased from 16 cents per share to 17 cents per share for 2017 over the last 60 days. The company has posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price surged 77.8% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>